Research Analysts Set Expectations for HURA Q2 Earnings

TuHURA Biosciences (NASDAQ:HURA) – Investment analysts at Zacks Small Cap issued their Q2 2025 EPS estimates for shares of TuHURA Biosciences in a research note issued on Tuesday, February 4th. Zacks Small Cap analyst J. Vandermosten forecasts that the company will earn ($0.09) per share for the quarter. Zacks Small Cap also issued estimates for TuHURA Biosciences’ Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS, Q1 2026 earnings at ($0.17) EPS and Q2 2026 earnings at ($0.17) EPS.

HURA has been the topic of several other reports. RODMAN&RENSHAW raised shares of TuHURA Biosciences to a “strong-buy” rating in a research note on Thursday, December 19th. Rodman & Renshaw began coverage on TuHURA Biosciences in a research report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target on the stock. Finally, Maxim Group assumed coverage on TuHURA Biosciences in a research report on Tuesday, November 5th. They issued a “buy” rating and a $15.00 price objective for the company.

TuHURA Biosciences Stock Performance

HURA stock opened at $4.46 on Wednesday. TuHURA Biosciences has a 1-year low of $2.84 and a 1-year high of $14.60. The firm has a 50 day moving average of $4.78.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in HURA. Suncoast Equity Management bought a new stake in shares of TuHURA Biosciences in the 4th quarter valued at about $421,000. Apollon Wealth Management LLC bought a new stake in TuHURA Biosciences in the fourth quarter valued at approximately $253,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of TuHURA Biosciences in the fourth quarter valued at approximately $61,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.